TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Significant Increase in Short Interest

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 46,900 shares, an increase of 47.5% from the November 15th total of 31,800 shares. Currently, 1.7% of the company's stock are short sold. Based on an average daily volume of 42,200 shares, the days-to-cover ratio is presently 1.1 days.

TriSalus Life Sciences Price Performance

NASDAQ TLSI traded down $0.06 during trading hours on Friday, hitting $3.91. The company's stock had a trading volume of 19,841 shares, compared to its average volume of 39,728. TriSalus Life Sciences has a 12 month low of $3.50 and a 12 month high of $10.42. The company's 50 day simple moving average is $4.19 and its two-hundred day simple moving average is $5.05. The company has a market cap of $119.23 million, a P/E ratio of -1.57 and a beta of 0.56.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TLSI. Oppenheimer initiated coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an "outperform" rating and a $10.00 price target on the stock. Canaccord Genuity Group cut their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. Northland Capmk raised TriSalus Life Sciences to a "strong-buy" rating in a research report on Friday, October 25th. Roth Capital upgraded shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Monday, November 11th. Finally, Northland Securities began coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They set an "outperform" rating and a $12.50 price objective for the company. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $12.08.

Institutional Trading of TriSalus Life Sciences

A number of large investors have recently made changes to their positions in the stock. Walleye Capital LLC purchased a new stake in TriSalus Life Sciences during the third quarter valued at $66,000. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences in the 3rd quarter worth approximately $92,000. Vestcor Inc purchased a new position in shares of TriSalus Life Sciences in the third quarter worth approximately $108,000. MSD Partners L.P. bought a new stake in TriSalus Life Sciences during the third quarter valued at approximately $184,000. Finally, Wolverine Asset Management LLC purchased a new stake in TriSalus Life Sciences during the second quarter valued at approximately $240,000. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.